Clinical trials
Leukemia, Myeloid clinical trials
Below are recruiting leukemia, myeloid clinical trials, each written for real people, not researchers. We’re tracking 575 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06810791RecruitingPhase 3
Comparing Chemotherapy Combos for High-Risk AML
This trial compares three chemotherapy combinations (HVA vs IA/DA or VA) for people with newly diagnosed high-risk acute myeloid leukemia (AML). It aims to find which treatment works better.
Guangzhou, GuangdongAges 18 years+ - NCT07425782RecruitingPhase 2
Venetoclax and azacitidine as consolidation for high-risk AML
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
Suzhou, JiangsuAges 18 years+ - NCT07420790Recruiting
Comparing two treatments for older AML patients before transplant
This trial looks back at how older adults with acute myeloid leukemia (AML) did when treated with either standard chemotherapy or a newer combination of venetoclax and decitabine, before a stem cell transplant. The goal is to see which treatment may lead to better outcomes.
Brescia, ItalyAges 18–75 - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT07392970RecruitingPhase 2
Motixafortide to improve AML treatment response after chemo
This trial tests if adding motixafortide can help find and eliminate leftover leukemia cells in people with AML who are in remission after initial chemotherapy. The goal is to make remission deeper and more durable.
St Louis, MissouriAges 18 years+ - NCT06827899RecruitingPhase 2
New combination therapy for older adults with untreated leukemia
This trial tests a three-drug combination (venetoclax, chidamide, and azacitidine) followed by another combination (decitabine plus MAG) for older adults with untreated acute myeloid leukemia (AML) who cannot have standard chemotherapy. It aims to offer a gentler but effective treatment option.
Xiamen, FujianAges 60 years+ - NCT06651866RecruitingPhase 1
Study of D-CMG for older adults with new AML
This trial tests a new drug combination called D-CMG for people aged 60–75 who have just been diagnosed with a type of leukemia (AML) and cannot have standard chemotherapy. The goal is to find a safe and effective dose.
Xiamen, FujianAges 60–75 - NCT06737523RecruitingPhase 1
A new combination therapy for relapsed or refractory AML
This trial tests a three-drug combination for patients whose AML has returned or not responded to prior treatment. It aims to see if adding a new drug (Chiglitazar) to standard treatments (Venetoclax and Azacitidine) can help control the leukemia.
Xiamen, FujianAges 18 years+ - NCT02781883RecruitingPhase 2
Test drug BP1001 with venetoclax and decitabine for AML
This Phase 2 study tests BP1001 added to venetoclax plus decitabine in adults with acute myeloid leukemia (AML). It aims to improve leukemia control in people who may not be able to get standard intensive chemotherapy.
Los Angeles, CaliforniaAges 18 years+ - NCT06613217RecruitingPhase 1
Oral PCLX-001 for relapsed or refractory AML
This trial tests an oral drug called PCLX-001 for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and can help control the leukemia.
Houston, TexasAges 18 years+ - NCT07321626RecruitingPhase 1
Romiplostim for platelet recovery after stem cell transplant
This trial tests if romiplostim, a drug that helps the body make platelets, can speed up platelet recovery after a special type of stem cell transplant from a half-matched donor. It may help reduce bleeding risk during the recovery period.
HangzhouAges 18 years+ - NCT07320235RecruitingPhase 1
Combination treatment for relapsed AML
This trial tests a new combination of drugs for people whose acute myeloid leukemia (AML) has come back or not responded after at least one prior treatment, and who have no other standard options. The goal is to see if adding imetelstat to other therapies can help.
New York, New YorkAges 18 years+ - NCT07304232RecruitingPhase 2
Chidamide after stem cell transplant for AML
This trial tests a drug called chidamide (Cidabenamide) as maintenance therapy after a stem cell transplant for people with intermediate or high-risk AML. The goal is to see if it helps prevent the leukemia from coming back.
Shijiazhuang, HebeiAges 18–75 - NCT05947344RecruitingPhase 1
Testing STI-8591 for advanced acute myeloid leukemia
This early-stage study tests STI-8591 in people with advanced acute myeloid leukemia (AML) or certain related blood cancers. It mainly aims to find a safe dose and see whether the treatment can work for patients whose disease did not respond to standard care or who cannot get it.
Hangzhou, ZhejiangAges 18 years+ - NCT06879847Recruiting
Clinical trial of radiation and chemotherapy before stem cell transplant for hard-to-treat AML
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
Suzhou, JiangsuAges 14–70 - NCT01210274Recruiting
Study how people resist azacitidine in blood cancers
This study looks at why some people with higher-risk blood cancers (MDS/AML-MD) do not respond as well to azacitidine. The goal is to learn the causes of resistance so future treatments may work better.
AntibesAges 18 years+ - NCT06885476Recruiting
NK cell infusion for AML patients with minimal cancer left
This trial tests if giving special immune cells from a donor can clear leftover leukemia cells in patients who are in remission but still have traces of cancer after chemotherapy.
Bologna, BOAges 18 years+ - NCT07270978RecruitingPhase 1
CD33-targeting cells for leukemia with leftover cancer cells
This trial tests a new treatment using special immune cells that target a protein called CD33 on leukemia cells. It's for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who still have small amounts of cancer cells left after other treatments.
Charlottesville, VirginiaAges 18 years+ - NCT07250646RecruitingPhase 1
Rebecsinib for secondary AML or high-risk myelofibrosis
This trial tests a new drug called rebecsinib for people with a certain type of leukemia (secondary acute myeloid leukemia) or a high-risk bone marrow disorder (myelofibrosis) that has come back or not responded to other treatments. The goal is to see if it works and is safe.
Duarte, CaliforniaAges 18 years+ - NCT07172204RecruitingPhase 2
Alternating chemo drugs for older or frailer adults with new AML
This trial tests a combination of two chemotherapy regimens given in turns for people with newly diagnosed acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. The goal is to find a gentler but effective treatment option.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07162116RecruitingPhase 1
Effect of XY0206 on heart rhythm in healthy Chinese volunteers
This trial tests whether a new drug called XY0206 affects the heart's electrical activity (QTc interval). Healthy participants take either XY0206, a placebo, or a control drug to compare effects. It helps ensure the drug is safe for the heart before testing in patients.
Zibo, ShandongAges 18–45 - NCT07147621Recruiting
Chemotherapy and thinking changes in blood cancer treatment
This study looks at whether chemotherapy for blood cancers like leukemia and lymphoma can affect thinking, memory, or concentration. It compares patients to a close family member or friend to see if any changes are related to the treatment.
Angers, Maine et LoireAges 18 years+ - NCT07153068RecruitingPhase 1/Phase 2
SupCD7 CART therapy for CD7 positive blood cancers
This trial tests a special immune cell therapy (SupCD7 CART) that targets a protein called CD7 on cancer cells. It is for people with certain types of blood cancers (like T-ALL/LBL or AML) that have come back or not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07130695RecruitingPhase 1
Olutasidenib for IDH1-mutated AML after initial treatment
This trial tests a drug called olutasidenib, either alone or with other treatments, to see if it can help keep your AML in remission after you've finished your first round of therapy. It's for people whose AML has a specific change in the IDH1 gene.
Richmond, VirginiaAges 18 years+
Hear when a new Leukemia, Myeloid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia, myeloid?
- Yes. Clin2 currently lists 575 recruiting leukemia, myeloid studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia, myeloid trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia, myeloid trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.